A5046162388- SARS-CoV-2 and COVID-19 Research
- PARP inhibition in cancer therapy
- Endodontics and Root Canal Treatments
- Blood Pressure and Hypertension Studies
- Neutropenia and Cancer Infections
- Respiratory Support and Mechanisms
- Long-Term Effects of COVID-19
- Systemic Lupus Erythematosus Research
- Potassium and Related Disorders
- Restless Legs Syndrome Research
- Colorectal Cancer Treatments and Studies
- Renal Transplantation Outcomes and Treatments
- Cancer Treatment and Pharmacology
- Thermal Regulation in Medicine
- COVID-19 Clinical Research Studies
- SARS-CoV-2 detection and testing
- Extracellular vesicles in disease
- Immune Cell Function and Interaction
- Diabetes Treatment and Management
- Signaling Pathways in Disease
- Oral and gingival health research
Xinyang Central Hospital
2023
Bayer (China)
2021
Kunming Medical University
2020
The First Hospital of Kunming
2020
People’s Hospital of Wenshan Prefecture
2020
Qingdao University
2002
Affiliated Hospital of Qingdao University
2002
Coronavirus disease 2019 (COVID-19) has spread worldwide. To date, no specific drug for COVID-19 been developed. Thus, this randomized, open-label, controlled clinical trial (ChiCTR2000029853) was performed in China. A total of 20 mild and common patients were enrolled randomly assigned to receive azvudine symptomatic treatment (FNC group), or standard antiviral (control group). The mean times the first nucleic acid negative conversion (NANC) ten FNC group control are 2.60 (SD 0.97; range...
Excessive proliferation and activation of B cells, resulting in the production various autoantibodies, is a crucial link significant feature pathogenesis systemic lupus erythematosus (SLE), as well pathological basis multiorgan damage. However, whether exosomes derived from human umbilical cord mesenchymal stem cells (hucMSCs-Exo) are involved immune regulation SLE has not been clarified. Therefore, our study aimed to investigate efficacy hucMSCs-Exo for treating SLE. peripheral blood...
Achieving target blood pressure (BP) goals in patients with chronic kidney disease (CKD) and uncontrolled hypertension is a challenge. Various studies have shown the efficacy of nifedipine gastrointestinal therapeutic system (GITS) 60 mg hypertension. However, there paucity clinical CKD. Hence, we conducted this study to evaluate effectiveness tolerability GITS Chinese CKD real-world settings. In prospective, multicenter, observational study, were given primary endpoint change office...
Tacrolimus and mycophenolate mofetil are the main cause of gastrointestinal symptoms in kidney transplant recipients. The possible induced mechanisms include increase drug exposure inhibition on gut associated lymph tissue. is with genetic polymorphisms CYP 3A4, 3A5 P-glycoprotein, changes function abundance intestinal bacterial flora, so on. Increasing tacrolimus promotes motility mycophenolic acid (MPA) absorption. MPA side effects its antiproliferative effect basal epithelial cells...